Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms

Author(s): Qing-Shan Li, Bang-Nian Shen, Hua-Jian Xu and Ban-Feng Ruan*

Volume 20 , Issue 12 , 2020

Page: [1415 - 1430] Pages: 16

DOI: 10.2174/1871520620666200422073622

Price: $65


Background: Almost 50% of metastatic melanomas harbor BRAF mutations. Since 2011, BRAF inhibitors have exhibited striking clinical benefits in BRAF-mutant melanoma patients. Unfortunately, their therapeutic effects are often temporary. The resistance mechanisms vary and can be broadly classified as MAPK reactivation-dependent and -independent. Elucidation of these resistance mechanisms provides new insights into strategies for overcoming resistance. Indeed, several alternative treatment strategies, including changes in the mode of administration, combinations of BRAF and MEK inhibitors, and immunotherapy have been verified as beneficial to BRAF inhibitor-resistant melanoma patients.

Prospect: In this review, we discuss promising strategies for overcoming drug resistance and highlighting the prospects for discovering strategies to counteract BRAF inhibitor resistance.

Keywords: Melanoma, BRAF, MAPK, inhibitors, mechanisms of resistance, immunotherapy.

Graphical Abstract
Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Cutaneous melanoma. Lancet, 2005, 365(9460), 687-701.
[] [PMID: 15721476]
Martinelli, E.; Morgillo, F.; Troiani, T.; Ciardiello, F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat. Rev., 2017, 53, 61-69.
[] [PMID: 28073102]
Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. Eur. J. Cancer, 2017, 73, 85-92.
[] [PMID: 28169047]
Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-954.
[] [PMID: 12068308]
Karoulia, Z.; Gavathiotis, E.; Poulikakos, P.I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer, 2017, 17(11), 676-691.
[] [PMID: 28984291]
Liu, R.; Zhang, T.; Zhu, G.; Xing, M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat. Commun., 2018, 9(1), 579.
[] [PMID: 29422527]
Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H.; Kaempgen, E.; Martin-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Mirakhur, B.; Guckert, M.E.; Swann, R.S.; Haney, P.; Goodman, V.L.; Chapman, P.B. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J. Clin. Oncol., 2013, 31(15)
Flaherty, K.T.; Robert, C.; Hersey, P.; Nathan, P.; Garbe, C.; Milhem, M.; Demidov, L.V.; Hassel, J.C.; Rutkowski, P.; Mohr, P.; Dummer, R.; Trefzer, U.; Larkin, J.M.; Utikal, J.; Dreno, B.; Nyakas, M.; Middleton, M.R.; Becker, J.C.; Casey, M.; Sherman, L.J.; Wu, F.S.; Ouellet, D.; Martin, A.M.; Patel, K.; Schadendorf, D.; Group, M.S. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med., 2012, 367(2), 107-114.
[] [PMID: 22663011]
Torres-Collado, A.X.; Knott, J.; Jazirehi, A.R. Reversal of resistance in targeted therapy of metastatic melanoma: Lessons learned from vemurafenib (BRAF(V600E)-Specific Inhibitor). Cancers (Basel), 2018, 10(6)
Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O’Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K.; Chapman, P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med., 2010, 363(9), 809-819.
[] [PMID: 20818844]
Falchook, G.S.; Long, G.V.; Kurzrock, R.; Kim, K.B.; Arkenau, T.H.; Brown, M.P.; Hamid, O.; Infante, J.R.; Millward, M.; Pavlick, A.C.; O’Day, S.J.; Blackman, S.C.; Curtis, C.M.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 2012, 379(9829), 1893-1901.
[] [PMID: 22608338]
Roskoski, R., Jr Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol. Res., 2019, 144, 19-50.
[] [PMID: 30877063]
Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O’Day, S.J.; Sosman, J.A.; Kirkwood, J.M.; Eggermont, A.M.M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R.J.; Flaherty, K.T.; McArthur, G.A.; Grp, B-S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011, 364(26), 2507-2516.
[] [PMID: 21639808]
Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H., Jr; Kaempgen, E.; Martín-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A.M.; Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M.E.; Goodman, V.; Chapman, P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380(9839), 358-365.
[]] [PMID: 22735384]
Menzies, A.M.; Long, G.V.; Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther., 2012, 6, 391-405.
[PMID: 23251089]
Smith, M.P.; Wellbrock, C. Molecular pathways: Maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance. Clin. Cancer Res., 2016, 22(24), 5966-5970.
[] [PMID: 27797970]
Luke, J.J.; Flaherty, K.T.; Ribas, A.; Long, G.V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol., 2017, 14(8), 463-482.
[] [PMID: 28374786]
Dronca, R.S.; Allred, J.B.; Perez, D.G.; Nevala, W.K.; Lieser, E.A.; Thompson, M.; Maples, W.J.; Creagan, E.T.; Pockaj, B.A.; Kaur, J.S.; Moore, T.D.; Marchello, B.T.; Markovic, S.N. Phase II study of Temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group study, N0675. Am. J. Clin. Oncol., 2014, 37(4), 369-376.
[] [PMID: 23357973]
Tolcher, A.W.; Peng, W.; Calvo, E. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. Mol. Cancer Ther., 2018, 17(1), 3-16.
[] [PMID: 29295962]
Erdmann, S.; Seidel, D.; Jahnke, H.G.; Eichler, M.; Simon, J.C.; Robitzki, A.A. Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci. Rep-Uk., 2019, 9, 11.
Ramos, P.; Bentires-Alj, M. Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance. Oncogene, 2015, 34(28), 3617-3626.
[] [PMID: 25263438]
Arozarena, I.; Wellbrock, C. Overcoming resistance to BRAF inhibitors. Ann. Transl. Med., 2017, 5(19), 387.
[] [PMID: 29114545]
Lim, S.Y.; Menzies, A.M.; Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123(S11), 2118-2129.
[] [PMID: 28543695]
Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur. J. Cancer, 2017, 73, 93-101.
[] [PMID: 28162869]
Kozar, I.; Margue, C.; Rothengatter, S.; Haan, C.; Kreis, S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim. Biophys. Acta Rev. Cancer, 2019, 1871(2), 313-322.
[] [PMID: 30776401]
Shi, H.; Hugo, W.; Kong, X.; Hong, A.; Koya, R.C.; Moriceau, G.; Chodon, T.; Guo, R.; Johnson, D.B.; Dahlman, K.B.; Kelley, M.C.; Kefford, R.F.; Chmielowski, B.; Glaspy, J.A.; Sosman, J.A.; van Baren, N.; Long, G.V.; Ribas, A.; Lo, R.S. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov., 2014, 4(1), 80-93.
[] [PMID: 24265155]
Johnson, D.B.; Childress, M.A.; Chalmers, Z.R.; Frampton, G.M.; Ali, S.M.; Rubinstein, S.M.; Fabrizio, D.; Ross, J.S.; Balasubramanian, S.; Miller, V.A.; Stephens, P.J.; Sosman, J.A.; Lovly, C.M. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell Melanoma Res., 2018, 31(3), 432-436.
[] [PMID: 29171936]
Rizos, H.; Menzies, A.M.; Pupo, G.M.; Carlino, M.S.; Fung, C.; Hyman, J.; Haydu, L.E.; Mijatov, B.; Becker, T.M.; Boyd, S.C.; Howle, J.; Saw, R.; Thompson, J.F.; Kefford, R.F.; Scolyer, R.A.; Long, G.V. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res., 2014, 20(7), 1965-1977.
[] [PMID: 24463458]
Britten, C.D. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol., 2013, 71(6), 1395-1409.
[] [PMID: 23443307]
Shi, H.; Moriceau, G.; Kong, X.; Lee, M.K.; Lee, H.; Koya, R.C.; Ng, C.; Chodon, T.; Scolyer, R.A.; Dahlman, K.B.; Sosman, J.A.; Kefford, R.F.; Long, G.V.; Nelson, S.F.; Ribas, A.; Lo, R.S. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun., 2012, 3, 724.
[] [PMID: 22395615]
Johnson, D.B.; Menzies, A.M.; Zimmer, L.; Eroglu, Z.; Ye, F.; Zhao, S.; Rizos, H.; Sucker, A.; Scolyer, R.A.; Gutzmer, R.; Gogas, H.; Kefford, R.F.; Thompson, J.F.; Becker, J.C.; Berking, C.; Egberts, F.; Loquai, C.; Goldinger, S.M.; Pupo, G.M.; Hugo, W.; Kong, X.; Garraway, L.A.; Sosman, J.A.; Ribas, A.; Lo, R.S.; Long, G.V.; Schadendorf, D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer, 2015, 51(18), 2792-2799.
[] [PMID: 26608120]
Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R.C.; Lee, H.; Chen, Z.; Lee, M.K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S.F.; McArthur, G.; Sosman, J.A.; Ribas, A.; Lo, R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468(7326), 973-977.
[] [PMID: 21107323]
Poulikakos, P.I.; Rosen, N. Mutant BRAF melanomas--dependence and resistance. Cancer Cell, 2011, 19(1), 11-15.
[] [PMID: 21251612]
Shi, H.; Kong, X.; Ribas, A.; Lo, R.S. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res., 2011, 71(15), 5067-5074.
[] [PMID: 21803746]
Sun, C.; Wang, L.; Huang, S.; Heynen, G.J.; Prahallad, A.; Robert, C.; Haanen, J.; Blank, C.; Wesseling, J.; Willems, S.M.; Zecchin, D.; Hobor, S.; Bajpe, P.K.; Lieftink, C.; Mateus, C.; Vagner, S.; Grernrum, W.; Hofland, I.; Schlicker, A.; Wessels, L.F.; Beijersbergen, R.L.; Bardelli, A.; Di Nicolantonio, F.; Eggermont, A.M.; Bernards, R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508(7494), 118-122.
[] [PMID: 24670642]
Girotti, M.R.; Pedersen, M.; Sanchez-Laorden, B.; Viros, A.; Turajlic, S.; Niculescu-Duvaz, D.; Zambon, A.; Sinclair, J.; Hayes, A.; Gore, M.; Lorigan, P.; Springer, C.; Larkin, J.; Jorgensen, C.; Marais, R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov., 2013, 3(2), 158-167.
[] [PMID: 23242808]
Johannessen, C.M.; Boehm, J.S.; Kim, S.Y.; Thomas, S.R.; Wardwell, L.; Johnson, L.A.; Emery, C.M.; Stransky, N.; Cogdill, A.P.; Barretina, J.; Caponigro, G.; Hieronymus, H.; Murray, R.R.; Salehi-Ashtiani, K.; Hill, D.E.; Vidal, M.; Zhao, J.J.; Yang, X.; Alkan, O.; Kim, S.; Harris, J.L.; Wilson, C.J.; Myer, V.E.; Finan, P.M.; Root, D.E.; Roberts, T.M.; Golub, T.; Flaherty, K.T.; Dummer, R.; Weber, B.L.; Sellers, W.R.; Schlegel, R.; Wargo, J.A.; Hahn, W.C.; Garraway, L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468(7326), 968-972.
[] [PMID: 21107320]
Mendoza, M.C.; Er, E.E.; Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci., 2011, 36(6), 320-328.
[] [PMID: 21531565]
Peng, S.B.; Henry, J.R.; Kaufman, M.D.; Lu, W.P.; Smith, B.D.; Vogeti, S.; Rutkoski, T.J.; Wise, S.; Chun, L.; Zhang, Y.; Van Horn, R.D.; Yin, T.; Zhang, X.; Yadav, V.; Chen, S.H.; Gong, X.; Ma, X.; Webster, Y.; Buchanan, S.; Mochalkin, I.; Huber, L.; Kays, L.; Donoho, G.P.; Walgren, J.; McCann, D.; Patel, P.; Conti, I.; Plowman, G.D.; Starling, J.J.; Flynn, D.L. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell, 2015, 28(3), 384-398.
[] [PMID: 26343583]
Whittaker, S.R.; Cowley, G.S.; Wagner, S.; Luo, F.; Root, D.E.; Garraway, L.A. Combined Pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors. Mol. Cancer Ther., 2015, 14(12), 2700-2711.
[] [PMID: 26351322]
Lu, H.; Liu, S.; Zhang, G.; Bin, W.; Zhu, Y.; Frederick, D.T.; Hu, Y.; Zhong, W.; Randell, S.; Sadek, N.; Zhang, W.; Chen, G.; Cheng, C.; Zeng, J.; Wu, L.W.; Zhang, J.; Liu, X.; Xu, W.; Krepler, C.; Sproesser, K.; Xiao, M.; Miao, B.; Liu, J.; Song, C.D.; Liu, J.Y.; Karakousis, G.C.; Schuchter, L.M.; Lu, Y.; Mills, G.; Cong, Y.; Chernoff, J.; Guo, J.; Boland, G.M.; Sullivan, R.J.; Wei, Z.; Field, J.; Amaravadi, R.K.; Flaherty, K.T.; Herlyn, M.; Xu, X.; Guo, W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550(7674), 133-136.
[] [PMID: 28953887]
Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kudchadkar, R.; Burris, H.A., III; Falchook, G.; Algazi, A.; Lewis, K.; Long, G.V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sun, P.; Allred, A.; Ouellet, D.; Kim, K.B.; Patel, K.; Weber, J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med., 2012, 367(18), 1694-1703.
[] [PMID: 23020132]
Van Allen, E.M.; Wagle, N.; Sucker, A.; Treacy, D.J.; Johannessen, C.M.; Goetz, E.M.; Place, C.S.; Taylor-Weiner, A.; Whittaker, S.; Kryukov, G.V.; Hodis, E.; Rosenberg, M.; McKenna, A.; Cibulskis, K.; Farlow, D.; Zimmer, L.; Hillen, U.; Gutzmer, R.; Goldinger, S.M.; Ugurel, S.; Gogas, H.J.; Egberts, F.; Berking, C.; Trefzer, U.; Loquai, C.; Weide, B.; Hassel, J.C.; Gabriel, S.B.; Carter, S.L.; Getz, G.; Garraway, L.A.; Schadendorf, D. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov., 2014, 4(1), 94-109.
[] [PMID: 24265153]
Trunzer, K.; Pavlick, A.C.; Schuchter, L.; Gonzalez, R.; McArthur, G.A.; Hutson, T.E.; Moschos, S.J.; Flaherty, K.T.; Kim, K.B.; Weber, J.S.; Hersey, P.; Long, G.V.; Lawrence, D.; Ott, P.A.; Amaravadi, R.K.; Lewis, K.D.; Puzanov, I.; Lo, R.S.; Koehler, A.; Kockx, M.; Spleiss, O.; Schell-Steven, A.; Gilbert, H.N.; Cockey, L.; Bollag, G.; Lee, R.J.; Joe, A.K.; Sosman, J.A.; Ribas, A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol., 2013, 31(14), 1767-1774.
[] [PMID: 23569304]
Wagle, N.; Emery, C.; Berger, M.F.; Davis, M.J.; Sawyer, A.; Pochanard, P.; Kehoe, S.M.; Johannessen, C.M.; Macconaill, L.E.; Hahn, W.C.; Meyerson, M.; Garraway, L.A. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol., 2011, 29(22), 3085-3096.
[] [PMID: 21383288]
Shi, H.; Moriceau, G.; Kong, X.; Koya, R.C.; Nazarian, R.; Pupo, G.M.; Bacchiocchi, A.; Dahlman, K.B.; Chmielowski, B.; Sosman, J.A.; Halaban, R.; Kefford, R.F.; Long, G.V.; Ribas, A.; Lo, R.S. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov., 2012, 2(5), 414-424.
[] [PMID: 22588879]
Emery, C.M.; Vijayendran, K.G.; Zipser, M.C.; Sawyer, A.M.; Niu, L.; Kim, J.J.; Hatton, C.; Chopra, R.; Oberholzer, P.A.; Karpova, M.B.; MacConaill, L.E.; Zhang, J.; Gray, N.S.; Sellers, W.R.; Dummer, R.; Garraway, L.A. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. USA, 2009, 106(48), 20411-20416.
[] [PMID: 19915144]
Shen, C.H.; Kim, S.H.; Trousil, S.; Frederick, D.T.; Piris, A.; Yuan, P.; Cai, L.; Gu, L.; Li, M.; Lee, J.H.; Mitra, D.; Fisher, D.E.; Sullivan, R.J.; Flaherty, K.T.; Zheng, B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat. Med., 2016, 22(9), 1056-1061.
[] [PMID: 27500726]
Martz, C.A.; Ottina, K.A.; Singleton, K.R.; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.P.; Sabatini, D.M.; Wood, K.C. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Signal., 2014, 7(357), ra121.
[] [PMID: 25538079]
Zhu, G.; Yi, X.; Haferkamp, S.; Hesbacher, S.; Li, C.; Goebeler, M.; Gao, T.; Houben, R.; Schrama, D. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells. Cancer Lett., 2016, 376(1), 43-52.
[] [PMID: 27000992]
Zhang, K.; Wong, P.; Salvaggio, C.; Salhi, A.; Osman, I.; Bedogni, B. Synchronized targeting of Notch and ERBB signaling suppresses melanoma tumor growth through inhibition of Notch1 and ERBB3. J. Invest. Dermatol., 2016, 136(2), 464-472.
[] [PMID: 26967479]
Aguissa-Touré, A.H.; Li, G. Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci., 2012, 69(9), 1475-1491.
[] [PMID: 22076652]
Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; Cooper, Z.A.; Chapman, P.B.; Solit, D.B.; Ribas, A.; Lo, R.S.; Flaherty, K.T.; Ogino, S.; Wargo, J.A.; Golub, T.R. Tumour micro environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487(7408), 500-504.
[] [PMID: 22763439]
Wilson, T.R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D.P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487(7408), 505-509.
[] [PMID: 22763448]
Villanueva, J.; Vultur, A.; Lee, J.T.; Somasundaram, R.; Fukunaga-Kalabis, M.; Cipolla, A.K.; Wubbenhorst, B.; Xu, X.; Gimotty, P.A.; Kee, D.; Santiago-Walker, A.E.; Letrero, R.; D’Andrea, K.; Pushparajan, A.; Hayden, J.E.; Brown, K.D.; Laquerre, S.; McArthur, G.A.; Sosman, J.A.; Nathanson, K.L.; Herlyn, M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18(6), 683-695.
[] [PMID: 21156289]
Corcoran, R.B.; Ebi, H.; Turke, A.B.; Coffee, E.M.; Nishino, M.; Cogdill, A.P.; Brown, R.D.; Della Pelle, P.; Dias-Santagata, D.; Hung, K.E.; Flaherty, K.T.; Piris, A.; Wargo, J.A.; Settleman, J.; Mino-Kenudson, M.; Engelman, J.A. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov., 2012, 2(3), 227-235.
[] [PMID: 22448344]
Das Thakur, M.; Stuart, D.D. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res., 2013, 73(20), 6106-6110.
[] [PMID: 24097822]
Seghers, A.C.; Wilgenhof, S.; Lebbé, C.; Neyns, B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res., 2012, 22(6), 466-472.
[] [PMID: 22584957]
Mateus, C.; Routier, E.; Roy, S.; Thomas, M.; Boussemart, L.; Glrault, I.; Chaput-Gras, N.; Vagner, S.; Cacenave, H.; Dalland, L.D.; Lau, M.R.; Bleam, M.R.; D’amelio, A.M.; Pfersch, S.; Caty, C.; Robert, C. Biomarker study evaluating the combination of dabrafenib (3) with trainetinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinih in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. J. Clin. Oncol., 2014, 32(15)
Algazi, A.P.; Othus, M.; Daud, A.; Mehnert, J.M.; Lao, C.D.; Kudchadkar, R.R.; Grossmann, K.F.; Lo, R.; Moon, J.; Kirkwood, J.M.; Ribas, A. SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF(V600E/k) mutant melanoma. J. Clin. Oncol., 2015, 33(15)
Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.E.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M. Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.P.V.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Shantha Kumara, H.M.C.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Vander Heiden, M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35(Suppl), S276-S304.
Kim, S.; Kim, H.T.; Suh, H.S. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: A systematic review and meta-analysis. J. Dermatolog. Treat., 2018, 29(3), 314-321.
[] [PMID: 28504036]
Larkin, J.; Ascierto, P.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Dutriaux, C.; Garbe, C.; Sovak, M.A.; Chang, I.; Choong, N.; Hack, S.P.; McArthur, G.A.; Ribas, A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 2014, 371(20), 1867-1876.
[] [PMID: 25265494]
Menzies, A.M.; Ashworth, M.T.; Swann, S.; Kefford, R.F.; Flaherty, K.; Weber, J.; Infante, J.R.; Kim, K.B.; Gonzalez, R.; Hamid, O.; Schuchter, L.; Cebon, J.; Sosman, J.A.; Little, S.; Sun, P.; Aktan, G.; Ouellet, D.; Jin, F.; Long, G.V.; Daud, A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann. Oncol., 2015, 26(2), 415-421.
[] [PMID: 25411413]
Long, G.V.; Trefzer, U.; Davies, M.A.; Kefford, R.F.; Ascierto, P.A.; Chapman, P.B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A.M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J.M.; Schadendorf, D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol., 2012, 13(11), 1087-1095.
[] [PMID: 23051966]
Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P.N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E.A.; Wong, B.; Tsang, G.; West, B.L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K.Y.; Artis, D.R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D’Andrea, K.; Koehler, A.; Stumm, M.; Lin, P.S.; Lee, R.J.; Grippo, J.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; Chapman, P.B.; Flaherty, K.T.; Xu, X.; Nathanson, K.L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.
[] [PMID: 20823850]
Schreuer, M.; Jansen, Y.; Planken, S.; Chevolet, I.; Seremet, T.; Kruse, V.; Neyns, B. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual centre, phase 2 clinical trial. Lancet Oncol., 2017, 18(4), 464-472.
[] [PMID: 28268064]
Infante, J.R.; Falchook, G.S.; Lawrence, D.P.; Weber, J.S.; Kefford, R.F.; Bendell, J.C.; Kurzrock, R.; Shapiro, G.; Kudchadkar, R.R.; Long, G.V.; Burris, H.A.; Kim, K.B.; Clements, A.; Peng, S.; Yi, B.; Allred, A.J.; Ouellet, D.; Patel, K.; Lebowitz, P.F.; Flaherty, K.T. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol., 2011, 29(18)
Long, G.V.; Stroyakovsky, D.L.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.M.G.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.J.; Chiarion-Sileni, V.; Lebbe, C.; Mandala, M.; Millward, M.; DeMarini, D.J.; Irani, J.G.; Le, N.; Casey, M.; Patel, K.; Flaherty, K. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF(V600E/K) mutation-positive cutaneous melanoma. J. Clin. Oncol., 2014, 32(15)
Long, G.V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.J.; Chiarion-Sileni, V.; Lebbe, C.; Mandalà, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J.B.; Hansson, J.; Utikal, J.; Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini, D.J.; Irani, J.G.; Swann, S.; Legos, J.J.; Jin, F.; Mookerjee, B.; Flaherty, K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 2015, 386(9992), 444-451.
[] [PMID: 26037941]
Flaherty, K.; Davies, M.A.; Grob, J.J.; Long, G.V.; Nathan, P.D.; Ribas, A.; Robert, C.; Schadendorf, D.; Frederick, D.T.; Hammond, M.R.; Jane-Valbuena, J.; Mu, X.J.; Squires, M.; Jaeger, S.A.; Lane, S.R.; Mookerjee, B.; Garraway, L.A. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs. D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J. Clin. Oncol., 2016, 34(15)
Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroyakovskiy, D.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsová, I.; Hauschild, A.; Mookerjee, B.; Legos, J.J.; Zhang, Y.; Lane, S.; Schadendorf, D. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann. Oncol., 2016, 27(suppl_6)
Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroiakovski, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsova, I.; Hauschild, A.; Lorigan, P.; Wolter, P.; Long, G.V.; Flaherty, K.; Nathan, P.; Ribas, A.; Martin, A.M.; Sun, P.; Crist, W.; Legos, J.; Rubin, S.D.; Little, S.M.; Schadendorf, D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med., 2015, 372(1), 30-39.
[] [PMID: 25399551]
Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J.S.; Kong, X.; Koya, R.C.; Flaherty, K.T.; Chapman, P.B.; Kim, M.J.; Hayward, R.; Martin, M.; Yang, H.; Wang, Q.; Hilton, H.; Hang, J.S.; Noe, J.; Lambros, M.; Geyer, F.; Dhomen, N.; Niculescu-Duvaz, I.; Zambon, A.; Niculescu-Duvaz, D.; Preece, N.; Robert, L.; Otte, N.J.; Mok, S.; Kee, D.; Ma, Y.; Zhang, C.; Habets, G.; Burton, E.A.; Wong, B.; Nguyen, H.; Kockx, M.; Andries, L.; Lestini, B.; Nolop, K.B.; Lee, R.J.; Joe, A.K.; Troy, J.L.; Gonzalez, R.; Hutson, T.E.; Puzanov, I.; Chmielowski, B.; Springer, C.J.; McArthur, G.A.; Sosman, J.A.; Lo, R.S.; Ribas, A.; Marais, R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med., 2012, 366(3), 207-215.
[] [PMID: 22256804]
Ribas, A.; Gonzalez, R.; Pavlick, A.; Hamid, O.; Gajewski, T.F.; Daud, A.; Flaherty, L.; Logan, T.; Chmielowski, B.; Lewis, K.; Kee, D.; Boasberg, P.; Yin, M.; Chan, I.; Musib, L.; Choong, N.; Puzanov, I.; McArthur, G.A. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol., 2014, 15(9), 954-965.
[] [PMID: 25037139]
Puzanov, I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J. Transl. Med., 2015, 13(S1), 1-2.
Larkin, J.M.G.; Yan, Y.B.; McArthur, G.A.; Ascierto, P.A.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.V.; Stroyakovskiy, D.; Thomas, L.; De La Cruz-Merino, L.; Atkinson, V.; Dutriaux, C.; Garbe, C.; Wongchenko, M.; Rooney, I.A.; Chang, I.S.; Hack, S.P.; Dreno, B.; Ribas, A. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J. Clin. Oncol., 2015, 33(15)
Ascierto, P.A.; McArthur, G.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Di Giacomo, A.M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Dutriaux, C.; Garbe, C.; Yan, Y.; Wongchenko, M.; Chang, I.; Hsu, J.J.; Koralek, D.O.; Rooney, I.; Ribas, A.; Larkin, J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol., 2016, 17(9), 1248-1260.
[] [PMID: 27480103]
McArthur, G.A.; Larkin, J.M.G.; Ascierto, P.A.; Hsu, J.J.; Yan, Y.B.; Rooney, I.A.; Koralek, D.; Dreno, B.; Ribas, A. Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. J. Clin. Oncol., 2016, 34(15)
Dossett, L.A.; Kudchadkar, R.R.; Zager, J.S. BRAF and MEK inhibition in melanoma. Expert Opin. Drug Saf., 2015, 14(4), 559-570.
[] [PMID: 25648338]
Richman, J.; Martin-Liberal, J.; Diem, S.; Larkin, J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin. Pharmacother., 2015, 16(9), 1285-1297.
[] [PMID: 26001180]
Spagnolo, F.; Ghiorzo, P.; Orgiano, L.; Pastorino, L.; Picasso, V.; Tornari, E.; Ottaviano, V.; Queirolo, P. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets Ther., 2015, 8, 157-168.
[] [PMID: 25653539]
Queirolo, P.; Picasso, V.; Spagnolo, F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat. Rev., 2015, 41(6), 519-526.
[] [PMID: 25944484]
Sweetlove, M.; Wrightson, E.; Kolekar, S.; Rewcastle, G.W.; Baguley, B.C.; Shepherd, P.R.; Jamieson, S.M. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front. Oncol., 2015, 5, 135.
[] [PMID: 26137449]
Sánchez-Hernández, I.; Baquero, P.; Calleros, L.; Chiloeches, A. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett., 2012, 314(2), 244-255.
[] [PMID: 22056813]
Khalili, J.S.; Yu, X.; Wang, J.; Hayes, B.C.; Davies, M.A.; Lizee, G.; Esmaeli, B.; Woodman, S.E. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin. Cancer Res., 2012, 18(16), 4345-4355.
[] [PMID: 22733540]
Poulikakos, P.I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M.T.; Salton, M.; Dahlman, K.B.; Tadi, M.; Wargo, J.A.; Flaherty, K.T.; Kelley, M.C.; Misteli, T.; Chapman, P.B.; Sosman, J.A.; Graeber, T.G.; Ribas, A.; Lo, R.S.; Rosen, N.; Solit, D.B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480(7377), 387-390.
[] [PMID: 22113612]
Greger, J.G.; Eastman, S.D.; Zhang, V.; Bleam, M.R.; Hughes, A.M.; Smitheman, K.N.; Dickerson, S.H.; Laquerre, S.G.; Liu, L.; Gilmer, T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther., 2012, 11(4), 909-920.
[] [PMID: 22389471]
Villanueva, J.; Infante, J.R.; Krepler, C.; Reyes-Uribe, P.; Samanta, M.; Chen, H.Y.; Li, B.; Swoboda, R.K.; Wilson, M.; Vultur, A.; Fukunaba-Kalabis, M.; Wubbenhorst, B.; Chen, T.Y.; Liu, Q.; Sproesser, K.; DeMarini, D.J.; Gilmer, T.M.; Martin, A.M.; Marmorstein, R.; Schultz, D.C.; Speicher, D.W.; Karakousis, G.C.; Xu, W.; Amaravadi, R.K.; Xu, X.; Schuchter, L.M.; Herlyn, M.; Nathanson, K.L. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep., 2013, 4(6), 1090-1099.
[] [PMID: 24055054]
Tolcher, A.W.; Patnaik, A.; Papadopoulos, K.P.; Rasco, D.W.; Becerra, C.R.; Allred, A.J.; Orford, K.; Aktan, G.; Ferron-Brady, G.; Ibrahim, N.; Gauvin, J.; Motwani, M.; Cornfeld, M. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother. Pharmacol., 2015, 75(1), 183-189.
[] [PMID: 25417902]
Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Peyton, J.D.; Thompson, D.S.; Lane, C.M.; Clark, B.L.; Rubin, M.S.; Trent, D.F.; Burris, H.A., III Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer, 2010, 116(17), 4122-4129.
[] [PMID: 20564157]
Morris, E.J.; Jha, S.; Restaino, C.R.; Dayananth, P.; Zhu, H.; Cooper, A.; Carr, D.; Deng, Y.; Jin, W.; Black, S.; Long, B.; Liu, J.; Dinunzio, E.; Windsor, W.; Zhang, R.; Zhao, S.; Angagaw, M.H.; Pinheiro, E.M.; Desai, J.; Xiao, L.; Shipps, G.; Hruza, A.; Wang, J.; Kelly, J.; Paliwal, S.; Gao, X.; Babu, B.S.; Zhu, L.; Daublain, P.; Zhang, L.; Lutterbach, B.A.; Pelletier, M.R.; Philippar, U.; Siliphaivanh, P.; Witter, D.; Kirschmeier, P.; Bishop, W.R.; Hicklin, D.; Gilliland, D.G.; Jayaraman, L.; Zawel, L.; Fawell, S.; Samatar, A.A. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov., 2013, 3(7), 742-750.
[] [PMID: 23614898]
Carlino, M.S.; Todd, J.R.; Gowrishankar, K.; Mijatov, B.; Pupo, G.M.; Fung, C.; Snoyman, S.; Hersey, P.; Long, G.V.; Kefford, R.F.; Rizos, H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol., 2014, 8(3), 544-554.
[] [PMID: 24476679]
Liu, F.; Yang, X.; Geng, M.; Huang, M.; Targeting, E.R.K. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm. Sin. B, 2018, 8(4), 552-562.
[] [PMID: 30109180]
Moschos, S.J.; Sullivan, R.J.; Hwu, W.J.; Ramanathan, R.K.; Adjei, A.A.; Fong, P.C.; Shapira-Frommer, R.; Tawbi, H.A.; Rubino, J.; Rush, T.S., III; Zhang, D.; Miselis, N.R.; Samatar, A.A.; Chun, P.; Rubin, E.H.; Schiller, J.; Long, B.J.; Dayananth, P.; Carr, D.; Kirschmeier, P.; Bishop, W.R.; Deng, Y.; Cooper, A.; Shipps, G.W.; Moreno, B.H.; Robert, L.; Ribas, A.; Flaherty, K.T. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight, 2018, 3(4), 18.
[] [PMID: 29467321]
Germann, U.A.; Furey, B.F.; Markland, W.; Hoover, R.R.; Aronov, A.M.; Roix, J.J.; Hale, M.; Boucher, D.M.; Sorrell, D.A.; Martinez-Botella, G.; Fitzgibbon, M.; Shapiro, P.; Wick, M.J.; Samadani, R.; Meshaw, K.; Groover, A.; DeCrescenzo, G.; Namchuk, M.; Emery, C.M.; Saha, S.; Welsch, D.J. Targeting the MAPK signaling pathway in cancer: Promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (Ulixertinib). Mol. Cancer Ther., 2017, 16(11), 2351-2363.
[] [PMID: 28939558]
Kidger, A.M.; Sipthorp, J.; Cook, S.J. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Pharmacol. Ther., 2018, 187, 45-60.
[] [PMID: 29454854]
Sullivan, R.J.; Infante, J.R.; Janku, F.; Wong, D.J.L.; Sosman, J.A.; Keedy, V.; Patel, M.R.; Shapiro, G.I.; Mier, J.W.; Tolcher, A.W.; Wang-Gillam, A.; Sznol, M.; Flaherty, K.; Buchbinder, E.; Carvajal, R.D.; Varghese, A.M.; Lacouture, M.E.; Ribas, A.; Patel, S.P.; DeCrescenzo, G.A.; Emery, C.M.; Groover, A.L.; Saha, S.; Varterasian, M.; Welsch, D.J.; Hyman, D.M.; Li, B.T. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a Phase I dose-escalation and expansion study. Cancer Discov., 2018, 8(2), 184-195.
[] [PMID: 29247021]
Kalialis, L.V.; Drzewiecki, K.T.; Klyver, H. Spontaneous regression of metastases from melanoma: Review of the literature. Melanoma Res., 2009, 19(5), 275-282.
[] [PMID: 19633580]
Maio, M. Melanoma as a model tumour for immuno-oncology. Ann. Oncol., 2012, 23(Suppl. 8), viii10-4.
[] [PMID: 22918922]
Melero, I.; Grimaldi, A.M.; Perez-Gracia, J.L.; Ascierto, P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res., 2013, 19(5), 997-1008.
[] [PMID: 23460531]
Sullivan, R.J.; Atkins, M.B. Cytokine therapy in melanoma. J. Cutan. Pathol., 2010, 37(Suppl. 1), 60-67.
[] [PMID: 20482677]
Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17(7), 2105-2116.
[] [PMID: 10561265]
Joseph, R.W.; Sullivan, R.J.; Harrell, R.; Stemke-Hale, K.; Panka, D.; Manoukian, G.; Percy, A.; Bassett, R.L.; Ng, C.S.; Radvanyi, L.; Hwu, P.; Atkins, M.B.; Davies, M.A. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother., 2012, 35(1), 66-72.
[] [PMID: 22130161]
Eigentler, T.K.; Weide, B.; de Braud, F.; Spitaleri, G.; Romanini, A.; Pflugfelder, A.; González-Iglesias, R.; Tasciotti, A.; Giovannoni, L.; Schwager, K.; Lovato, V.; Kaspar, M.; Trachsel, E.; Menssen, H.D.; Neri, D.; Garbe, C. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin. Cancer Res., 2011, 17(24), 7732-7742.
[] [PMID: 22028492]
Kirkwood, J.M.; Manola, J.; Ibrahim, J.; Sondak, V.; Ernstoff, M.S.; Rao, U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res., 2004, 10(5), 1670-1677.
[] [PMID: 15014018]
Eggermont, A.M.; Suciu, S.; Santinami, M.; Testori, A.; Kruit, W.H.; Marsden, J.; Punt, C.J.; Salès, F.; Gore, M.; Mackie, R.; Kusic, Z.; Dummer, R.; Hauschild, A.; Musat, E.; Spatz, A.; Keilholz, U.; Group, E.M. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 2008, 372(9633), 117-126.
[] [PMID: 18620949]
Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363(8), 711-723.
[] [PMID: 20525992]
Brunet, J.F.; Denizot, F.; Luciani, M.F.; Roux-Dosseto, M.; Suzan, M.; Mattei, M.G.; Golstein, P. A new member of the immunoglobulin superfamily--CTLA-4. Nature, 1987, 328(6127), 267-270.
[] [PMID: 3496540]
Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Chen, T.T.; Berman, D.M.; Wolchok, J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur. J. Cancer, 2013, 49, S11-S11.
Wolchok, J.D.; Weber, J.S.; Maio, M.; Neyns, B.; Harmankaya, K.; Chin, K.; Cykowski, L.; de Pril, V.; Humphrey, R.; Lebbé, C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann. Oncol., 2013, 24(8), 2174-2180.
[] [PMID: 23666915]
Weber, J.S.; Kähler, K.C.; Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol., 2012, 30(21), 2691-2697.
[] [PMID: 22614989]
Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; Davidson, N.; Richards, J.; Maio, M.; Hauschild, A.; Miller, W.H., Jr; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T.T.; Humphrey, R.; Hoos, A.; Wolchok, J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364(26), 2517-2526.
[] [PMID: 21639810]
Sherrill, B.; Wang, J.; Kotapati, S.; Chin, K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br. J. Cancer, 2013, 109(1), 8-13.
[] [PMID: 23787916]
Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366(26), 2443-2454.
[] [PMID: 22658127]
Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000, 192(7), 1027-1034.
[] [PMID: 11015443]
Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol., 2012, 24(2), 207-212.
[] [PMID: 22236695]
Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R.W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M.A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X.N.; Iannone, R.; Ebbinghaus, S.W.; Kang, S.P.; Daud, A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384(9948), 1109-1117.
[] [PMID: 25034862]
Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
[] [PMID: 25891173]
Iyer, P.C.; Dadu, R.; Gule-Monroe, M.; Busaidy, N.L.; Ferrarotto, R.; Habra, M.A.; Zafereo, M.; Williams, M.D.; Gunn, G.B.; Grosu, H.; Skinner, H.D.; Sturgis, E.M.; Gross, N.; Cabanillas, M.E. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J. Immunother. Cancer, 2018, 6(1), 68.
[] [PMID: 29996921]
Ribas, A.; Robert, C.; Daud, A.; Hodi, F.S.; Wolchok, J.D.; Kefford, R.; Patnaik, A.; Hwu, W.J.; Weber, J.S.; Joshua, A.; Hersey, P.; Gangadhar, T.C.; Joseph, R.W.; Dronca, R.S.; Zarour, H.M.; Ebbinghaus, S.; Gergich, K.; Li, X.Y.; Kang, S.P.; Hamid, O. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. J. Clin. Oncol., 2013, 31(15)
Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; Humphrey, R.; Hodi, F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res., 2009, 15(23), 7412-7420.
[] [PMID: 19934295]
Hodi, F.S.; Kefford, R.; Hamid, O.; Daud, A.; Wolchok, J.D.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Joshua, A.M.; Hersey, P. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with Melanoma (MEL). J. Clin. Oncol., 2014, 32(18_suppl), LBA9000.
Force, J.; Salama, A.K. First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther., 2017, 6, 1-10.
[] [PMID: 28243579]
Sosman, J.; Sznol, M.; McDermott, D.F.; Carvajal, R.; Lawrence, D.P.; Topalian, S.L.; Wigginton, J.M.; Kollia, G.; Gupta, A.; Hodi, F.S. Clinical activity and safety of anti-programmed death-1 (Pd-1) (Bms-936558/Mdx-1106/Ono-4538) in Patients (Pts) with Advanced Melanoma (Mel). Ann. Oncol., 2012, 23, 361-361.
Weber, J.S.; Kudchadkar, R.R.; Gibney, G.T.; Yu, B.; Cheng, P.; Martinez, A.J.; Kroeger, J.; Gallenstein, D.; Richards, A.; Welsh, E.; Zhao, X.; Qu, X.; Chen, A. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, Ipilimumab (IPI). J. Clin. Oncol., 2014, 32(15_suppl), 3009-3009.
Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
[] [PMID: 22658128]
Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; Dronca, R.; Gangadhar, T.C.; Patnaik, A.; Zarour, H.; Joshua, A.M.; Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; Boasberg, P.; Tumeh, P.C.; Chmielowski, B.; Ebbinghaus, S.W.; Li, X.N.; Kang, S.P.; Ribas, A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 2013, 369(2), 134-144.
[] [PMID: 23724846]
Hamid, O.; Sosman, J.A.; Lawrence, D.P.; Sullivan, R.J.; Ibrahim, N.; Kluger, H.M.; Boasberg, P.D.; Flaherty, K.; Hwu, P.; Ballinger, M.; Mokatrin, A.; Kowanetz, M.; Chen, D.S.; Hodi, F.S. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol., 2013, 31(15)
Ott, P.A.; Hodi, F.S.; Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res., 2013, 19(19), 5300-5309.
[] [PMID: 24089443]
Lutzky, J.; Antonia, S.J.; Blake-Haskins, A.; Li, X.; Robbins, P.B.; Shaiabl, A.M.; Vasseill, J.; Ibrahim, R.A.; Khleif, S.; Segal, N.H. A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors. J. Clin. Oncol., 2014, 32(15)
Segal, N.H.; Antonia, S.J.; Brahmer, J.R.; Maio, M.; Blake-Haskins, A.; Li, X.; Vasselli, J.; Ibrahim, R.A.; Lutzky, J.; Khieif, S. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol., 2014, 32(15)
Callahan, M.K.; Ott, P.A.; Odunsi, K.; Bertolini, S.V.; Pan, L.S.; Venhaus, R.R.; Karakunnel, J.J.; Hodi, F.S.; Wolchok, J.D. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. J. Clin. Oncol., 2014, 32(15)
Bellmunt, J.; Petrylak, D.P.; Powles, T.; Braiteh, F.; Vogelzang, N.; Cruz, C.; Burris, H.; Eder, J.P.; Fine, G.; Teng, M.S. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in Pts with metastatic Urothelial Bladder Cancer (UBC). Ann. Oncol., 2014, 25(suppl_4), iv280.
Heery, C.R.; Coyne, G.H.O.; Madan, R.A.; Schlom, J.; von Heydebreck, A.; Cuillerot, J.M.; Sabzevari, H.; Gulley, J.L. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J. Clin. Oncol., 2014, 32(15)
Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; Shaheen, M.; Ernstoff, M.S.; Minor, D.; Salama, A.K.; Taylor, M.; Ott, P.A.; Rollin, L.M.; Horak, C.; Gagnier, P.; Wolchok, J.D.; Hodi, F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med., 2015, 372(21), 2006-2017.
[] [PMID: 25891304]
Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; Burke, M.M.; Caldwell, A.; Kronenberg, S.A.; Agunwamba, B.U.; Zhang, X.; Lowy, I.; Inzunza, H.D.; Feely, W.; Horak, C.E.; Hong, Q.; Korman, A.J.; Wigginton, J.M.; Gupta, A.; Sznol, M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 2013, 369(2), 122-133.
[] [PMID: 23724867]
Chapman, P.B.; D’Angelo, S.P.; Wolchok, J.D. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med., 2015, 372(21), 2073-2074.
[] [PMID: 25891305]
Frederick, D.T.; Piris, A.; Cogdill, A.P.; Cooper, Z.A.; Lezcano, C.; Ferrone, C.R.; Mitra, D.; Boni, A.; Newton, L.P.; Liu, C.; Peng, W.; Sullivan, R.J.; Lawrence, D.P.; Hodi, F.S.; Overwijk, W.W.; Lizée, G.; Murphy, G.F.; Hwu, P.; Flaherty, K.T.; Fisher, D.E.; Wargo, J.A. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res., 2013, 19(5), 1225-1231.
[] [PMID: 23307859]
Wilmott, J.S.; Long, G.V.; Howle, J.R.; Haydu, L.E.; Sharma, R.N.; Thompson, J.F.; Kefford, R.F.; Hersey, P.; Scolyer, R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res., 2012, 18(5), 1386-1394.
[] [PMID: 22156613]
Ribas, A.; Hodi, F.S.; Callahan, M.; Konto, C.; Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med., 2013, 368(14), 1365-1366.
[] [PMID: 23550685]
Sharma, P.; Hu-Lieskovan, S.; Wargo, J.A.; Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 2017, 168(4), 707-723.
[] [PMID: 28187290]
Boni, A.; Cogdill, A.P.; Dang, P.; Udayakumar, D.; Njauw, C.N.; Sloss, C.M.; Ferrone, C.R.; Flaherty, K.T.; Lawrence, D.P.; Fisher, D.E.; Tsao, H.; Wargo, J.A. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res., 2010, 70(13), 5213-5219.
[] [PMID: 20551059]
Cooper, Z.A.; Juneja, V.R.; Sage, P.T.; Frederick, D.T.; Piris, A.; Mitra, D.; Lo, J.A.; Hodi, F.S.; Freeman, G.J.; Bosenberg, M.W.; McMahon, M.; Flaherty, K.T.; Fisher, D.E.; Sharpe, A.H.; Wargo, J.A. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res., 2014, 2(7), 643-654.
[] [PMID: 24903021]
Corcoran, R.B.; André, T.; Atreya, C.E.; Schellens, J.H.M.; Yoshino, T.; Bendell, J.C.; Hollebecque, A.; McRee, A.J.; Siena, S.; Middleton, G.; Muro, K.; Gordon, M.S.; Tabernero, J.; Yaeger, R.; O’Dwyer, P.J.; Humblet, Y.; De Vos, F.; Jung, A.S.; Brase, J.C.; Jaeger, S.; Bettinger, S.; Mookerjee, B.; Rangwala, F.; Van Cutsem, E. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov., 2018, 8(4), 428-443.
[] [PMID: 29431699]
Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R.L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.
[] [PMID: 22281684]
Al-Marrawi, M.Y.; Saroya, B.S.; Brennan, M.C.; Yang, Z.; Dykes, T.M.; El-Deiry, W.S. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol. Ther., 2013, 14(8), 703-710.
[] [PMID: 23792568]
Cheng, H.; Chang, Y.; Zhang, L.; Luo, J.; Tu, Z.; Lu, X.; Zhang, Q.; Lu, J.; Ren, X.; Ding, K. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. J. Med. Chem., 2014, 57(6), 2692-2703.
[] [PMID: 24588073]
Awadallah, F.M.; Abou-Seri, S.M.; Abdulla, M.M.; Georgey, H.H. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity. Eur. J. Med. Chem., 2015, 94, 397-404.
[] [PMID: 25778995]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy